Evidence map›Paper›PMID 40752894›Full record

Trial reportStroke and vascular neurology2026

Treatment of acute intracerebral haemorrhage with a Chinese herbal formula (Shengdi Dahuang Decoction): a multicentre, double-blind, randomised, placebo-controlled trial.

Zhihuan Sun, Xiaoyu Zhou, Jingyan Xiang, Feng Wang, Yan Han, Yongmei Guo, Zongqi Zhang, Fan Gong, Mingzhe Wang, Dezhi Liu and 7 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stroke and vascular neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04200781 (A Randomized, Controlled, Double-blind, Multi-center Clinical Study of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04200781 phase4unknown statusnot on this map

A Randomized, Controlled, Double-blind, Multi-center Clinical Study of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke

TypeinterventionalSponsorShuGuang HospitalRan2019 to 2022Enrolled464ConditionsHemorrhagic StrokeArmsGranules of Shengdi Dahuang Decoction, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zhihuan SunLonghua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0002-8669-313X
Xiaoyu ZhouShanghai Tenth People's Hospital, Shanghai, China.ORCID 0000-0002-3947-1788
Jingyan XiangShanghai Sixth People's Hospital, Shanghai, China.
Feng WangShanghai Seventh People's Hospital, Shanghai, China.
Yan HanShanghai University of Traditional Chinese Medicine Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.ORCID 0000-0002-7654-0906
Yongmei GuoShanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zongqi ZhangShanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Fan GongShanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Mingzhe WangShanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Dezhi LiuShanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Weidong PanShanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Haiyan TangShanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Tingting LiShanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jingsi ZhangShanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shan JiangShanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jihan HuangShanghai University of TCM, Shanghai, China.
Xiaofei YuLonghua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China neurologyyuxiaofei@shutcm.edu.cn.ORCID 0000-0002-0188-6654

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importancePer preliminary studies, Shengdi Dahuang Decoction (SDD) is potentially effective for acute intracerebral haemorrhage (ICH); however, its effectiveness has not been rigorously assessed in extensive randomised clinical trials.

objectiveTo evaluate whether SDD can improve 90-day functional outcomes in patients with ICH.

designRandomised, double-blind, placebo-controlled clinical trial included patients with acute ICH within 4 hours of symptom onset at five hospitals in Shanghai, China.

interventionsPatients were randomised 1:1 to receive either SDD granules (each sachet contained 15 g of raw MAIN OUTCOMES: The primary outcome measure was the proportion of patients with a score ranging 0-1 on the modified Rankin Scale (mRS) on the 90th day.

resultsOf the total 1211 participants with cerebral haemorrhage assessed for eligibility, 483 were enrolled. Of this, 242 participants were randomly assigned to receive SDD granules and 241 to receive placebo granules (mean age, 62.7 years; 72.9% male). Among these, 112 (46.3%) and 84 (34.9%) patients in the SDD and placebo groups, respectively, had an mRS score of 0-1 on the 90th day (adjusted relative risk 1.20, 95% CI 1.00 to 1.43; p=0.046) . The proportion of patients with poor clinical outcomes (mRS score of 5 or 6 at 90 days) was higher in the placebo group (11.2%) than in the SDD group (5.4%) (p=0.021). The 90-day mortality rate (p=0.299), 7-day National Institute of Health Stroke Scale score (p=0.583), 7-day Glasgow Coma Scale score (p=0.577), 24-hour haematoma enlargement rate (p=0.675) or 7-day relative perihaematomal oedema did not significantly differ (p=0.343) between the groups. The incidence of adverse events between the two groups did not differ significantly (p>0.05).

conclusionsIn patients with acute ICH, incorporating SDD as a supplementary intervention alongside guideline-directed treatments may help enhance 90-day functional outcomes; however, more clinical trials are required to further prove its efficacy. TRIAL REGISTRATION NUMBER: NCT04200781.

Indexed as

Cerebral HemorrhageDrugs, Chinese HerbalAgedChinaDisability EvaluationDouble-Blind MethodFemaleFunctional StatusHumansMaleMiddle AgedRecovery of FunctionRheumTime FactorsTreatment OutcomeDrugs, Chinese HerbalCerebrovascular DisordersClinical TrialHemorrhage

Identifiers

PMID40752894
PMCPMC13151873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.